BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a California-based rare disease biotechnology company, has presented a 13-study research programme at the 2026 American Society for Bone and Mineral Research Annual Meeting in Boston, highlighting new imaging findings involving Voxzogo (vosoritide) in children with achondroplasia, including infants. Announced on October 9, 2026, the programme also features Phase 3 hypochondroplasia evidence and preclinical research involving investigational long-acting treatment BMN 333, extending the company’s clinical development strategy beyond its established indication for improving linear growth.
The most clinically intriguing development involves a post hoc imaging analysis examining changes in the foramen magnum and craniocervical junction, anatomical regions associated with potentially serious neurological complications in achondroplasia. BioMarin described the results as encouraging, but its conference announcement did not provide numerical measurements, patient counts or statistical comparisons for the imaging endpoints. The findings consequently provide exploratory evidence about skeletal development rather than confirmation that Voxzogo prevents spinal cord compression or reduces the need for surgery.
The meeting also arrives at an important regulatory moment. BioMarin has submitted a supplemental New Drug Application to the United States Food and Drug Administration seeking to expand Voxzogo treatment into hypochondroplasia following positive Phase 3 results, while a separate application seeking full approval in achondroplasia has a February 28, 2027 target decision date. These are distinct regulatory processes, and the medicine’s current United States authorisation remains limited to increasing linear growth in children with achondroplasia whose growth plates are open.
What do the new Voxzogo imaging findings reveal about skull development in achondroplasia?
Achondroplasia is caused by genetic changes involving fibroblast growth factor receptor 3, or FGFR3, which disrupt the normal process through which cartilage is converted into bone. Although disproportionate short stature is its most recognisable characteristic, the condition can affect skeletal development throughout the body, including the spine, limbs and base of the skull. Some infants and children develop narrowing around the foramen magnum, the opening through which the brainstem connects with the spinal cord.
The new analysis examines whether vosoritide treatment influences growth-related dimensions of the foramen magnum and craniocervical junction. The research draws on imaging data from a randomized, double-blind, placebo-controlled clinical trial, giving investigators an opportunity to assess anatomical changes against a controlled treatment comparison. However, because the imaging assessment was conducted post hoc, its findings require more cautious interpretation than prospectively defined primary efficacy outcomes.
The potential clinical relevance extends beyond linear growth. Abnormalities around the skull base can contribute to cervicomedullary compression, which may require neurological monitoring and, in selected cases, surgical decompression. A treatment capable of favourably influencing skeletal development in this region could have implications for long-term care, but the latest announcement does not establish that such anatomical changes translate into fewer neurological complications.
BioMarin has not disclosed the magnitude of the reported imaging differences, whether they reached statistical significance or how consistently the findings appeared across age groups. It also has not presented evidence establishing reduced surgical intervention, respiratory complications or neurological impairment through this analysis. Those outcomes would require appropriately designed studies with sufficient follow-up and clinically meaningful assessments.
Why is early treatment becoming an important focus of Voxzogo research?
The emphasis on infants reflects the biology of skeletal development. Important changes in skull and spinal anatomy occur during early childhood, making the timing of any growth-modifying intervention a relevant clinical question. Vosoritide acts on signalling pathways that counteract excessive FGFR3 activity, promoting endochondral bone growth while growth plates remain open.
BioMarin has previously reported improvements in body proportionality, arm span and growth-related measurements among children beginning treatment at younger ages. Research presented in March 2026 indicated that children who started Voxzogo before two years of age demonstrated improvements in upper-to-lower body segment ratios relative to untreated comparison populations. Those findings contribute to the rationale for investigating whether early treatment affects additional skeletal structures.
However, evidence that earlier treatment improves particular growth measurements is not equivalent to demonstrating prevention of structural complications. Differences in baseline anatomy, severity and natural development can influence outcomes, particularly when treated patients are compared with historical or observational reference groups. The skull imaging research may help identify suitable anatomical measurements for future trials, but it does not yet justify a definitive conclusion about long-term neurological protection.
For clinicians, a more complete evidence package would need to connect imaging changes with functional outcomes and clinical assessments. These could include neurological findings, respiratory evaluations and longitudinal measurements of craniovertebral anatomy. Such evidence would be particularly relevant when evaluating treatment during infancy, when monitoring for achondroplasia-associated complications already forms an important part of specialised care.
How strong are the Phase 3 hypochondroplasia results supporting BioMarin’s FDA submission?
The hypochondroplasia programme has a substantially more mature evidence base than the exploratory skull imaging analysis. The Phase 3 CANOPY-HCH-3 trial enrolled 81 children aged three to under 18 years, randomly assigning 41 participants to vosoritide and 40 to placebo for 52 weeks. Its primary endpoint measured the change from baseline in annualized growth velocity, allowing investigators to evaluate treatment-related growth against a blinded control group.
Results published in NEJM Evidence on September 9, 2026, demonstrated a least-squares mean treatment difference of 2.33 centimetres per year in favour of vosoritide, with a 95% confidence interval of 1.85 to 2.82 centimetres per year and a p-value below 0.0001. Annualized growth velocity increased by 1.95 centimetres per year from baseline in the treatment group, compared with a decline of 0.39 centimetres per year in the placebo group. These results established statistical superiority on the prespecified primary endpoint.
Secondary outcomes also supported the treatment effect. Compared with placebo, vosoritide produced a 2.35-centimetre improvement in standing height, a 0.39 improvement in height Z-score and a 1.03-centimetre improvement in arm span after 52 weeks. The arm-span difference was statistically significant at p=0.0082, suggesting that the growth effect extended beyond the primary measure.
The trial did not establish that one year of treatment improves final adult height or reduces the longer-term medical complications associated with hypochondroplasia. Although numerical improvements in quality-of-life assessments were reported, those observations should not be treated as definitive evidence of improved physical functioning. Continued follow-up will be necessary to determine whether the growth advantage persists and whether it translates into broader patient outcomes.
What do the safety findings indicate about extending vosoritide to hypochondroplasia?
The published Phase 3 trial reported adverse events in 87.8% of vosoritide recipients and 72.5% of placebo recipients. No Grade 3 or higher adverse events, adverse-event-related treatment discontinuations or deaths were reported during the 52-week study. BioMarin characterised the safety profile as consistent with its experience in achondroplasia, although the higher overall adverse-event incidence in the active-treatment group remains relevant to interpretation.
Vosoritide’s existing United States prescribing information identifies temporary reductions in blood pressure as an important safety concern. Commonly reported adverse reactions include injection-site reactions, vomiting, elevated alkaline phosphatase measurements, joint pain and abdominal discomfort. These established risks remain important when assessing use in a new population, even when a clinical trial does not identify an unexpected safety signal.
A further consideration is treatment burden. Voxzogo is administered as a daily subcutaneous injection, and children may require prolonged treatment while their growth plates remain open. Its clinical value therefore involves balancing measured growth benefits with tolerability, administration requirements and the experience of patients and caregivers.
The hypochondroplasia evidence includes an earlier investigator-sponsored study with three years of follow-up in 13 children. BioMarin reported sustained growth improvements in that smaller extension cohort, including a 0.72 improvement in mean height standard deviation score over three years. Although encouraging, the small population and extension-study design limit how confidently those findings can be generalized to the broader population.
What is the difference between the two Voxzogo regulatory applications?
BioMarin is pursuing two separate regulatory objectives that should not be confused. In achondroplasia, Voxzogo already has United States accelerated approval for increasing linear growth in children with open growth plates. The company’s current supplemental application seeks full approval, supported by longer-term evidence examining growth and other skeletal outcomes.
The FDA accepted that application in July 2026 and established February 28, 2027, as its target action date. BioMarin’s supporting package includes evidence related to adult height, body proportionality and arm span, alongside long-term safety data. A favourable decision would address the existing accelerated approval framework, but it would not automatically authorise every additional clinical benefit being investigated.
The hypochondroplasia application represents a proposed expansion into a different genetic skeletal condition. BioMarin submitted the supplemental application following positive Phase 3 findings, while European and other regional regulatory submissions are also being pursued. As of the October 9 announcement, no regulator had approved vosoritide for treating hypochondroplasia.
BioMarin estimates that approximately 14,000 children with hypochondroplasia within its global commercial footprint could be eligible for treatment. This is a company-estimated potentially addressable population, not a count of diagnosed patients who are certain to receive therapy. Its potential 2027 launch timeline remains dependent on regulatory authorisation and subsequent commercial preparations.
Could investigational BMN 333 offer a weekly alternative to daily Voxzogo injections?
BioMarin’s next-generation skeletal growth programme includes BMN 333, an investigational long-acting version of its C-type natriuretic peptide approach. The company presented preclinical research at ASBMR examining bone growth and skeletal microarchitecture in juvenile mice and nonhuman primates. These findings complement earlier Phase 1 pharmacological data but do not constitute evidence of improved growth in children.
In June 2026, BioMarin reported Phase 1 results showing sustained exposure following BMN 333 administration in healthy adult volunteers. The results supported the possibility of once-weekly dosing, compared with the daily administration required for Voxzogo. However, sustained drug exposure does not establish equivalent or superior efficacy, and the appropriate dose must still be evaluated in children with achondroplasia.
The company began enrolling patients in the registration-enabling Phase 2/3 ASPEN study in April 2026. The programme is designed to identify an appropriate dose and subsequently compare BMN 333 with vosoritide in children who have not previously received growth-promoting treatment. A data update from the dose-finding portion is expected in 2027.
A successful weekly formulation could potentially reduce injection frequency and simplify aspects of treatment administration. Nevertheless, less frequent dosing would need to preserve appropriate efficacy and safety across the dosing interval. The ASPEN programme provides an opportunity to examine these questions directly rather than relying on pharmacokinetic comparisons alone.
Why are bone strength and skeletal proportions receiving more attention in achondroplasia studies?
BioMarin’s ASBMR programme includes presentations examining bone strength, quantitative computed tomography measurements of bone mineral density and the molecular effects of vosoritide on bone growth and mineralisation. These investigations broaden the scientific focus beyond annualized growth velocity, the endpoint that supported the medicine’s original United States accelerated approval. They also reflect growing interest in understanding whether altered skeletal growth produces changes in bone quality and structural development.
In achondroplasia, disproportionate bone growth can influence limb alignment, spinal anatomy and musculoskeletal function. An increase in bone length does not necessarily establish improvements in bone strength, joint mobility or daily activity. Imaging and mechanical assessments can help investigate these relationships, but their interpretation requires appropriate reference populations and clinically validated measurements.
The conference presentations cover several different methodologies, including comparisons with untreated achondroplasia reference populations. Such studies may identify patterns associated with treatment, but differences in age, growth stage and baseline disease characteristics can influence imaging findings. Observational comparisons therefore need to be distinguished from randomized treatment effects.
BioMarin’s October announcement did not provide complete numerical findings for the bone-strength or bone-density posters. Consequently, it does not yet support a definitive conclusion that vosoritide reduces fracture risk, improves skeletal strength or prevents orthopedic complications. The additional research is valuable for identifying potential benefits that can be investigated through more comprehensive clinical follow-up.
How important is Voxzogo to BioMarin’s revenue and investor outlook?
Voxzogo has become one of BioMarin Pharmaceutical Inc.’s largest commercial products. During the second quarter of 2026, the company reported Voxzogo revenue of $253 million, compared with $221 million a year earlier, representing growth of approximately 14%. Global patient numbers increased by more than 20% year over year, with the company reporting particularly strong demand among younger children.
BioMarin increased its full-year 2026 Voxzogo revenue guidance to between $1 billion and $1.05 billion in August. The product accounted for approximately 26% of the company’s $990 million in second-quarter revenue, demonstrating its importance to the broader rare disease portfolio. A successful hypochondroplasia label expansion could create an additional commercial opportunity, although the company has not disclosed a definitive revenue forecast for the proposed indication.
BioMarin’s latest overall revenue guidance stands at $3.875 billion to $3.925 billion for 2026. The company is also integrating medicines acquired through its April 2026 acquisition of Amicus Therapeutics, creating additional growth opportunities alongside integration costs and financing obligations. Its second-quarter net income declined to $45 million from $241 million a year earlier, reflecting acquisition-related expenses and other operating factors despite revenue growth.
BioMarin shares closed at approximately $54.80 on October 9, 2026, down about 0.2% during the session and roughly 4.2% over the preceding five trading sessions. The muted response on the announcement date should not be interpreted as a direct assessment of the skull imaging findings, particularly because the release did not disclose their full quantitative results. Longer-term investor sentiment is more likely to be influenced by regulatory outcomes, commercial execution and evidence supporting sustained product growth.
What does the broader ASBMR programme reveal about BioMarin’s pipeline priorities?
The 13-study programme extends beyond achondroplasia and hypochondroplasia into other disorders of skeletal development and mineralisation. Presentations include research concerning X-linked hypophosphatemia, hypophosphatasia and ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency, commonly known as ENPP1 deficiency. These investigations employ different scientific approaches and should not be interpreted as components of a single clinical development programme.
One presentation covers 52-week results from the Phase 3 ENERGY 3 trial of BMN 401 in children with ENPP1 deficiency. However, BioMarin announced in May that the study had achieved only one of its two co-primary endpoints, demonstrating increased plasma inorganic pyrophosphate without improvement in the radiographic assessment of rickets severity. The company subsequently disclosed in August that it had discontinued BMN 401 development across all indications.
The inclusion of the ENERGY 3 presentation therefore represents continued scientific reporting of an unsuccessful pivotal programme, not renewed development activity or a newly successful clinical result. Other hypophosphatasia presentations examine disease burden, quality-of-life effects and observational assessment tools, while experimental research investigates approaches to altering bone-related biological pathways. Their scientific relevance should be considered independently of the commercial prospects of Voxzogo or BMN 333.
This distinction also illustrates the differing maturity of BioMarin’s skeletal disease research. Voxzogo has an established commercial and regulatory position in achondroplasia, its hypochondroplasia programme has positive peer-reviewed Phase 3 data under regulatory consideration, and BMN 333 remains investigational despite entering late-stage clinical development. Earlier research involving additional skeletal disorders is further from establishing patient treatment benefits.
What will determine whether BioMarin’s latest findings improve long-term treatment outcomes?
The strongest immediate opportunity concerns the proposed hypochondroplasia indication, where randomized Phase 3 evidence has demonstrated statistically significant improvements across several growth measures. Regulatory approval would make vosoritide available within a new authorised population, subject to the final prescribing information. However, subsequent real-world experience and long-term studies will remain important for understanding treatment duration, functional outcomes and the persistence of benefit.
For achondroplasia, the new skull imaging research addresses a different and potentially consequential question about skeletal development beyond height. Quantitative anatomical measurements, prespecified clinical assessments and evidence involving neurological outcomes would help determine whether the observed imaging findings translate into measurable health benefits. The current exploratory analysis provides a reason for further investigation rather than a confirmed reduction in complications.
BMN 333 introduces a separate clinical and commercial question about whether a longer-acting treatment can provide comparable growth outcomes with fewer injections. The ongoing ASPEN study will be important for determining dose selection and generating direct comparative evidence. Until those results become available, its potential advantages remain a development hypothesis supported by early pharmacological and preclinical findings.
BioMarin’s next major regulatory milestone is the February 28, 2027 FDA target action date for full Voxzogo approval in achondroplasia, alongside the continuing review process for the proposed hypochondroplasia indication. The company’s expanding skeletal research programme shows that treatment evaluation is moving toward questions involving anatomical development, bone health and longer-term functioning. Whether those broader findings ultimately change clinical practice will depend on their ability to demonstrate meaningful patient benefits beyond the established improvement in linear growth.
